Ozempic and Weight-Loss Drugs Do Not Increase Birth Defect Risk: New Study

A systematic review from the University of St Andrews suggests that weight-loss medications and diabetes treatments known as GLP-1 receptor agonists do not increase the risk of major birth defects when taken around the time of pregnancy.

The research, published in the American Journal of Obstetrics and Gynaecology, represents the largest analysis of its kind to date. Researchers examined more than 49,000 pregnancies over a 20-year period involving exposure to GLP-1 receptor agonists, which include medications such as Ozempic, Wegovy, and Mounjaro.

Scope of the Systematic Review

The study focused on the safety profile of GLP-1 receptor agonists (GLP-1 RAs) during the periconceptional period. These medications are designed to mimic a hormone that regulates insulin secretion and appetite, and they have become widely used for both the management of type 2 diabetes and the treatment of obesity.

By reviewing two decades of data, the University of St Andrews team sought to determine if there was a meaningful correlation between the use of these drugs and the occurrence of major congenital malformations. The findings indicate that these medications do not raise the risk of major birth defects.

This data provides a significant evidence base for clinicians and patients, particularly as these drugs are increasingly prescribed to individuals of reproductive age who may be hoping to conceive or who may conceive unexpectedly while on the medication.

Clinical Context and Implications

The use of GLP-1 RAs during pregnancy has historically been a point of caution due to a lack of extensive human data. Most manufacturers have previously advised against the use of these drugs during pregnancy, often citing a lack of sufficient safety data rather than confirmed adverse effects.

The St Andrews study offers grounded reassurance for women who find themselves pregnant while using these medications. By analyzing a massive cohort of over 49,000 pregnancies, the researchers were able to provide a more statistically robust assessment of risk than previous, smaller studies.

The findings are particularly relevant given the rising popularity of these medications for weight management, which can impact overall reproductive health and pregnancy outcomes. While the study suggests a lack of increased risk for major birth defects, the researchers maintain a cautious tone regarding the broader application of these findings.

Remaining Uncertainties

Despite the positive results regarding birth defects, the researchers emphasize that these findings should be viewed with caution. The study focuses specifically on major birth defects rather than all possible pregnancy outcomes or long-term developmental effects.

Medical professionals continue to evaluate the optimal timing for discontinuing these medications before conception. Because GLP-1 RAs can significantly suppress appetite and affect nutrient absorption, the impact on fetal growth and maternal nutrition remains a subject of ongoing clinical interest.

The University of St Andrews findings contribute to a growing body of evidence that may eventually lead to updated clinical guidelines for the use of GLP-1 receptor agonists in patients of childbearing potential.